BACKGROUND: Long-term outcomes for childhood left ventricular noncompaction (LVNC) are uncertain. We examined late outcomes for children with LVNC enrolled in a national population-based study.
L eft ventricular (LV) noncompaction (LVNC)
is an increasingly recognized type of cardiomyopathy 1 characterized by the presence of an extensive trabeculated myocardium separated into 2 distinct compacted and noncompacted layers. 2, 3 The American Heart Association classifies it as a genetic cardiomyopathy caused by arrested myocardial development, 2,4,5 although on occasion, cases have been reported to develop postnatally in response to alterations of preload. 6, 7 The European Society of Cardiology lists LVNC as an unclassified cardiomyopathy. 8 In childhood LVNC, different phenotypes have been observed, including dilated, hypertrophic, restrictive, isolated (not associated with abnormal physiology), and that associated with congenital heart disease, individually or in combination. 1, 9 Whereas isolated LVNC is thought to have a relatively good prognosis, 10 LVNC with a dilated phenotype (LVNC-D) is associated with worse short-term outcomes. 1, 11 Long-term outcomes for children with LVNC remain uncertain. In addition, it is unclear whether outcomes are determined solely by the extent and severity of cardiac dysfunction or whether the presence of LVNC confers additional adverse prognostic information.
We examined late outcomes for children with LVNC enrolled in the NACCS (National Australian Childhood Cardiomyopathy Study), a population-based, longitudinal cohort study with long-term follow-up extending to 30 years.
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METHODS
The NACCS study includes all children in Australia with primary cardiomyopathy who were diagnosed at 0 to <10 years of age between January 1, 1987, and December 31, 1996 . Local institutional ethics committee approval was obtained from participating centers. The methodology has been detailed previously. 12, 15, 16 In brief, study subjects were enrolled through site visits undertaken from 1997 to 2007 by the same 3 investigators visiting all 9 pediatric cardiac centers and an additional 12 hospitals caring for children with cardiac conditions (Appendix). The data that support the findings of this study are available from the corresponding author on reasonable request.
Study subjects were identified from multiple sources, including local cardiology databases, echocardiographic records, and International Classification of Diseases, Ninth Revision, Clinical Modification medical record codes. Children with structural heart disease and progressive neuromuscular disorders were excluded. Examination of centralized records compiled by the Australian Bureau of Statistics indicated that there were no children with sudden death as their initial symptom who were diagnosed at autopsy. Ethics committee approval was obtained from each participating institution.
Prospective follow-up was arranged for any subjects who were not being followed up regularly. Study questionnaires were used to extract standardized clinical and echocardiographic data obtained during follow-up.
Definitions
Cardiomyopathies were classified during the course of site visits according to the existing World Health Organization cardiomyopathy classification 5 by a single observer after reviewing all relevant investigations, including all available cardiac imaging. 12 Study subjects were classified on the basis of echocardiographic findings as having LVNC if there was the characteristic morphological appearance comprising multiple trabeculations, deep intertrabecular recesses seen on color flow, and a 2-layered structure of the myocardium with a ratio of noncompacted to compacted myocardium of >2:1 in systole. 17 An experienced pediatric pathologist with cardiac expertise reviewed available pathological specimens, including cardiac histology.
A family history of cardiomyopathy was defined by the presence of at least 1 affected first-or second-degree relative with LVNC identified from case notes or from familial screening.
The presence of congestive heart failure was based on signs and symptoms recorded by the attending physician. Sudden death was defined as a sudden and unexpected death in a child within 4 hours of new symptoms.
14 Serial echocardiograms at presentation, those closest to 3, 6, and 12 months after diagnosis and then at yearly intervals during follow-up, were reviewed by a single observer, and measurements of LV dimensions, wall thickness, and fractional shortening (FS) in those without regional wall motion abnormalities were expressed as z scores based on body surface area or age in the case of FS. 18, 19 LVNC-D was defined as present if the LV was dilated with reduced systolic function (FS z score <−2.0 and/or LV ejection
Clinical Perspective
What Is New?
• Long-term outcomes for children with left ventricular noncompaction (LVNC) are uncertain.
• The NACCS (National Australian Childhood Cardiomyopathy Study) uniquely represents the longest and most complete longitudinal cohort study of childhood cardiomyopathy.
• This population-based study defines the incidence, presentation, and long-term outcomes for LVNC diagnosed during childhood.
• Risk-adjusted analyses in this study showed that subjects with LVNC and dilated physiology tended to experience worse survival than matched subjects with dilated cardiomyopathy, with a 2-fold higher risk of death or transplantation.
What Are the Clinical Implications?
• Our findings support consideration of LVNC as a distinct cardiomyopathy phenotype in pediatric patients.
• Children with LVNC who develop heart failure at an early age may benefit from specialist care delivered in pediatric heart failure centers. ORIGINAL RESEARCH ARTICLE fraction <45%). Similar echocardiographic criteria were used to classify subjects with dilated cardiomyopathy (DCM) in the absence of LVNC. 13 Restrictive pathophysiology in subjects with LVNC was diagnosed from echocardiography and/ or cardiac catheterization in subjects with impaired diastolic function and normal LV size with preserved systolic function. 12 A hypertrophic phenotype was defined by otherwise unexplained LV free wall or septal hypertrophy (diastolic wall thickness z score >2).
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Statistical Analysis
Statistical analyses were performed with IBM SPSS Statistics version 23 and R statistical package version 3.3.1. Incidence rates were calculated from the age-specific population at risk between 1987 and 1997. 20, 21 Continuous variables were described as median (interquartile interval) and compared, when relevant, by use of the Wilcoxon sum-rank test. Categorical variables were described through proportions and compared by use of the Fisher exact test.
Analysis of Long-Term Outcome
Our primary end point was the combined end point of death or transplantation from the time of presentation. The end points of death and transplantation were combined into a composite primary end point because cardiac transplantation was not widely used in the early part of the study.
The Kaplan-Meier method was used to estimate long-term transplantation-free survival probabilities, and the log-rank test was used for unadjusted comparison of these probabilities between subjects with LVNC-D and those with DCM.
Normalization of LV function in subjects with LVNC-D was considered to have occurred on the first occasion when the LV end-diastolic dimension (LVEDD) z score was <2.0 and the LV FS z score was >−2.0. Cumulative incidence curves were constructed for the competing events of normalization of LV function, death or transplantation before normalization, and remaining alive, transplantation free, and without normalization. The cumulative incidence curves were constructed so as to represent the first-encountered competing event.
Because of the relatively low case numbers, only univariable Cox regression analysis was performed to examine the association between variables and the combined outcome of death or transplantation. Variables analyzed in a univariate fashion were age at presentation, sex, body surface area, presentation with congestive heart failure, consanguinity, family history of cardiomyopathy, baseline LVEDD z score, and baseline FS z score.
The current value and the current rate of change of echocardiographic measurements (LVEDD z score and FS z score) were both analyzed as time-dependent variables. The current rate of change was approximated as the difference between the 2 most recent measurements before the event divided by the time between the measurements. Normalization of LV function was also analyzed as a time-dependent variable.
Propensity-Score Analysis
Cases with missing values were excluded from regression and propensity-score analyses. Two separate propensity-score methods were used to risk-adjust for differences in clinical profiles between subjects with LVNC-D and those with DCM: propensity-score matching and inverse probability of treatment weighting. A propensity score was generated for each case by performing a logistic regression with LVNC-D binary indicator as the dependent variable. Baseline clinical and investigative covariables were used. These were age at presentation, sex, year of presentation, body surface area, congestive heart failure at diagnosis, consanguinity, family history of cardiomyopathy, and LVEDD z score and FS z score on the first available echocardiogram.
For propensity-score matching, subjects were matched 1 to 1 on their propensity score without replacement with the use of the greedy matching method with a caliper width equal to 0.2 of the SD of the logit of the propensity score. In the matched sample, paired t tests were used for continuous data, whereas the McNemar test, which compares the discordance of 2 dichotomous outcomes, was used to compare categorical variables. Similarly, long-term freedom from death/transplantation was compared with the test proposed by Klein and Moeschberger. 22 For the propensity-score inverse probability of treatmentweighting analysis, the contribution of each individual to Kaplan-Meier estimates or Cox regression is weighted by the inverse of the probability that he or she belongs to the corresponding group, which is estimated from the propensity scores obtained from the aforementioned logistic regression. Intuitively, these weights generate a pseudopopulation in which both groups to be compared are balanced with respect to the measured confounders. This enables the comparison of these groups and estimation of the population-average (marginal) effect of LVNC-D on the combined end point of death or transplantation, expressed as a hazard ratio. The analysis was performed according to best practice recommendations.
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RESULTS
Incidence Rate of LVNC
During the 10-year period, there were 29 newly diagnosed cases of LVNC, making up 9.2% of the NACCS study population. The mean annual at-risk population (number of Australian children 0-10 years of age) during this period was 2 532 347, 20, 21 leading to a mean annual incidence of newly diagnosed cases of 0.11 (95% confidence interval [CI], 0.08-0.16) per 100 000 individuals at risk. Table 1 shows the mean annual incidence according to age at presentation. The highest incidence was in the first year of life (0.83 [95% CI, 0.51-1.30] per 100 000), representing a >5-fold increase compared with subjects ≥1 year of age at the time of presentation. During this same time period, there were 175 newly diagnosed cases of DCM in patients who did not have LVNC. ORIGINAL RESEARCH ARTICLE had dilated phenotype. One subject had restrictive phenotype, and 1 subject with Barth syndrome had isolated LVNC without associated cardiac dysfunction. Twenty of 29 subjects (69%) were male. Associated anomalies in 9 subjects included Barth syndrome in 7, left bronchial stenosis in 1, and bile duct hypoplasia requiring liver transplantation in the remaining subject. Two first cousins, both with consanguineous parents, were found to have a truncating mutation in the ALPK3 gene, and 1 subject with Barth syndrome had a complex I respiratory chain enzyme deficiency. Echocardiography was available in all 29 cases. Additional confirmation of LVNC was available from characteristic findings on LV angiography in 12 subjects and direct examination of the heart (explant or autopsy) in 11.
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Presentation and Clinical Characteristics
The most common symptom at diagnosis was congestive cardiac failure in 24 patients (83%); 2 subjects were diagnosed on routine family screening, including 1 with Barth syndrome who has never developed symptoms. The remaining 3 subjects had a diagnosis of LVNC following feeding difficulties, an abnormal chest x-ray, and onset of supraventricular tachycardia in a premature infant. Further clinical details are presented in Table 2 .
Light microscopic findings from autopsy, explantation at the time of transplantation, or endomyocardial biopsy was abnormal in 19 of 21 available cases and included myocyte hypertrophy, nuclear irregularity, and endocardial fibroelastosis.
Long-Term Outcomes
No subjects were lost to follow-up. The median duration of follow-up was 6.8 (interquartile interval, 0.7-24.0) years for all subjects and 24.7 (23.3-27.7) years for survivors. Of the 27 subjects with dilated phenotype, 19 died or underwent heart transplantation (including 5 cases of sudden death). The subject with restrictive physiology died during follow-up, and the subject with Barth syndrome and isolated LVNC remains alive with normal cardiac function 24 years after diagnosis. The 2 related subjects with an ALPK3 mutation progressed from a dilated to a hypertrophic phenotype.
Normalization of LV systolic function occurred in 8 of 29 subjects (28%), all with a dilated phenotype, including 4 of 7 subjects (57%) with Barth syndrome and both subjects who developed a hypertrophic phenotype. Two of 8 subjects who had normalization of LV function later died suddenly; 2 patients redeveloped a dilated phenotype with 1 patient undergoing cardiac transplantation 14 years later. Two subjects have normal LV size but with reduced function at late follow-up, and the remaining 2 subjects continue to have normal LV size and systolic function at the late follow-up. Parental consanguinity, † n (%) 4 (14)
Barth syndrome, n (%) 7 (24) Congestive heart failure at diagnosis, n (%)
24 ( At diagnosis, the median noncompacted to compacted myocardial thickness ratio in systole, measured from echocardiography at the site of maximal involvement, was 2.6 (IQI, 2.1-3.2). In diastole, it was 2.3 (2.0-2.5). Data were incomplete in 2 subjects, who were excluded from propensity-score analyses. IQI indicates interquartile interval.
*On first available echocardiogram. †There were 4 subjects with parental consanguinity, including 2 siblings.
Circulation. Figure 1 shows survival for all patients, and Figure 2 shows the cumulative proportion of patients experiencing each competing end point after presentation for all 29 patients. At 15 years after diagnosis, 21% of patients with LVNC were alive with normal LV function, and 31% were alive without transplantation or normalization of LV function.
Of 8 subjects in the NACCS registry with Barth syndrome, 7 had LVNC. Of these, 2 died (both with sudden death), 1 underwent transplantation, 2 had normal LV systolic function at the latest follow-up, and 2 are alive with a persisting dilated phenotype. There was a nominal association toward patients with Barth syndrome having better survival at 15 years (patients with Barth syndrome, 71% [95% CI, 39-100] versus those without Barth syndrome, 36% [95% CI, 16-57], P=0.08). Table 3 shows the association between clinical factors and the combined end point of death or transplantation determined by univariable Cox regression. Favorable prognostic variables included male sex, presence of a positive family history, and a higher FS z score at any time during follow-up. A larger LVEDD z score during follow-up was associated with worse prognosis. Familial LVNC and male sex were unrelated to survival in the absence of Barth syndrome.
Of the 29 patients with LVNC, long-term therapy with an angiotensin-converting enzyme inhibitor was used in 13, a β-blocker was used in 6, and either an angiotensin-converting enzyme inhibitor or a β-blocker was used in 16.
Comparison of LVNC-D and DCM
Compared with the 175 patients with isolated DCM, patients with LVNC-D were more likely to be male and of lower weight at presentation. Baseline echocardiographic measurements were similar (Table 4) . Unadjusted freedom from death or transplantation was similar between LVNC-D and DCM groups ( Figure 3A) .
Propensity-score matching yielded 24 matched pairs. The clinical and echocardiographic characteristics among matched cases are presented in Table 5 . Among matched pairs, there was a nominal association (P=0.08) for subjects with LVNC to have worse transplantation-free survival compared to those with those with DCM at 15 years, as shown in Figure 3B .
Long-term therapy with an angiotensin-converting enzyme inhibitor or a β-blocker was used in 12 of 24 (50%) matched LVNC-D cases and 11 the 24 (46%) of the matched DCM cases.
Propensity-score analysis using inverse probability of treatment-weighted Cox regression showed that LVNC was associated with a greater risk of death or transplantation (hazard ratio, 2.3; 95% CI, 1.4-3.8; P=0.0012; Figure 3C ).
DISCUSSION
The NACCS uniquely represents the longest and most complete longitudinal cohort study of childhood cardiomyopathy with a median follow-up of survivors of nearly 25 years. Ongoing follow-up of this cohort has provided novel information for long-term outcomes for childhood cardiomyopathy. 13, 14 Our population-based study defines the incidence, presentation, and long-term outcomes for LVNC diagnosed during childhood. In particular, long-term outcomes for children with LVNC associated with a DCM phenotype were worse than those for matched children with DCM.
Incidence
Previously considered an uncommon cardiomyopathy type, LVNC accounted for nearly 10% of all childhood cardiomyopathy cases in the NACCS study. The incidence of newly diagnosed cases in our study was 0.11 per 100 000 at-risk subjects per year, with the highest incidence being during the first year of life, similar to children with dilated and hypertrophic cardiomyopathy from the NACCS registry. The overall proportion of patients with LVNC in our study was similar to that of a single-center study from Texas Children's Hospital 24 and somewhat greater than the 4.8% reported from the North American PCMR (Pediatric Cardiomyopathy Registry). 1 In another study from the United Kingdom, 3% of children <16 years of age with myocardial disease resulting in new-onset heart failure were diagnosed with LVNC. 25 The higher proportion of patients with LVNC in our study may reflect systematic case classification by a single observer. 
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Inheritance
Multiple modes of LVNC inheritance have been described; X-linked recessive and autosomal dominant are most common, whereas autosomal recessive and mitochondrial inheritance have also been described. Our study provides further evidence for a genetic basis for LVNC, with 31% of subjects having a positive family history of cardiomyopathy, which is comparable to published reports of 16% to 44%. 24, [26] [27] [28] [29] A significant proportion of these subjects had Barth syndrome, accounting for the male preponderance.
Long-Term Outcomes for LVNC
In our study, long-term outcome was worse than previously described in some other series, with only 45% of subjects alive and transplantation free 15 years after presentation. Our findings contrast with a 10-year transplantation-free survival of 60% to 86% in studies from Toronto and Texas 24, 27 and 93% in a study from Japan. 26 The higher mortality in our population-based study most likely reflects a high proportion of sick, young infants, many of whom died within 1 year after presentation. The low mortality in the Japanese study may conversely reflect a high proportion of asymptomatic cases as a result of a systematic childhood screening program in Japan.
Rates of death or transplantation for subjects in our study were also higher than those reported by the PCMR. 1 The PCMR study comprised children with variable LVNC phenotypes, including a greater proportion without cardiac dysfunction. Outcomes for children with LVNC and dilated physiology in the PCMR were also poor, with a hazard ration for death or transplantation of >6 compared with subjects with isolated LVNC.
In our study, risk factors on univariable regression analysis for death/transplantation included female sex, sporadic LVNC (nonfamilial), and worse LV systolic As in other studies, severity of systolic dysfunction was the most important predictor of survival at any time during follow-up. The association toward better survival in patients with Barth syndrome is unexpected. We postulate that this may be related to more systematic screening and earlier diagnosis of LVNC given the presence of an underlying syndrome.
Comparison With DCM
The 15-year transplantation-free survival of 45% for patients with LVNC is worse than the 56% 20-year survival reported from the NACCS for children with DCM. 13 Propensity-score analyses in this study showed that subjects with LVNC-D tended to experience worse survival than matched subjects with DCM and that LVNC-D was associated with a 2-fold higher risk of death or transplantation.
The frequency of use of remodeling therapy was similar in both the LVNC-D and DCM groups, suggest- 
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ing that better outcomes for the matched DCM were not the result of the use of remodeling heart failure therapy. However, our study was not designed to examine the impact of any particular heart failure therapy. Our findings contrast with studies of adult subjects with DCM and LVNC such as that by Amzulescu and colleagues, 30 who examined 162 subjects with DCM undergoing cardiac magnetic resonance imaging. Those who met magnetic resonance imaging criteria for LVNC had outcomes similar to those of remaining subjects, leading the authors to argue against a noncompaction phenotype being a more severe form of DCM. These contrasting findings most likely reflect a different spectrum of causes for both conditions in adult subjects.
Higher rates of death or transplantation in children with LVNC compared with those with isolated DCM may reflect a different genetic basis and in some cases the absence of a reversible cause such a lymphocytic myocarditis, which is present in a significant proportion of children with DCM. 12, 13 We also speculate that the spectrum of genetic causes responsible for childhood LVNC may differ from those of affected adults, leading to a more severe clinical course for those who develop heart failure at a young age. Rates of sudden death in patients with LVNC were comparatively high, and an undulating phenotype or fluctuating LV systolic function 24 was observed in a significant proportion of subjects. Taken together, these findings support consideration of LVNC as a distinct cardiomyopathy phenotype in pediatric patients.
The use of circulatory support and adult-based heart failure therapies in children with DCM has increased in recent years. Routine screening combined with cascade genetic testing may contribute to the earlier diagnosis of cardiomyopathy in at-risk family members. These developments are most likely responsible for the improved outcomes noted in children with DCM who have received care in specialized pediatric heart failure centers in the past 3 decades. 31 Children with LVNC, who develop symptoms at an early age and have worse outcomes than those with DCM, might therefore benefit similarly from specialist care delivered in high-volume pediatric centers.
Limitations
Our population-based study had a high proportion of symptomatic young subjects with dilated physiology. Outcomes from the present study cannot be extrapolated to children who have LVNC with other phenotypes and to those without symptoms diagnosed during routine family screening or as a result of genetic testing. Genetic and mitochondrial testing was not routinely available for all subjects during the study period, and the proportion of cases with one of these pathogeneses may therefore have been underestimated. The limited number of cases precluded multivariable analysis of risk factors for death or transplantation. Furthermore, propensity-score analyses, like any other type of analysis, are inherently unable to account for unmeasured variables, including more sophisticated parameters of LV function. 
Conclusions
In our population-based study, LVNC accounted for 9.2% of all cardiomyopathies diagnosed in Australia during the first decade of life. Most subjects were diagnosed during infancy with a dilated phenotype, after symptoms of congestive heart failure. Survival free from transplantation at 15 years after diagnosis was 45%. Transplantation-free survival was worse for subjects with the greatest degree of LV systolic dysfunction at any time during follow-up, and subjects with LVNC-D had worse outcomes than matched subjects with DCM.
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